Sino Biopharmaceutical Surges 5% in Early Trading with $500 Million Acquisition of Shanghai Laixin Pharmaceuticals

Market Watcher

Jul 16, 2025

Sino Biopharmaceutical (01177.HK) opened over 5% higher in Hong Kong trading. At press time, shares gained 1.88% to HK$6.49 with turnover reaching HK$706 million.

The pharmaceutical giant announced a $500 million deal to acquire 95.09% equity in Shanghai Laixin Pharmaceuticals. Combined with its existing 4.91% stake obtained during Laixin's Series C funding, this transaction will make Laixin a wholly-owned subsidiary of Sino Biopharmaceutical.

Industry records reveal Laixin's significant licensing achievements: In May 2023, AstraZeneca secured exclusive global rights to develop and commercialize LM-305, involving $55 million upfront payment plus potential milestones up to $545 million. By November 2024, Merck & Co. obtained worldwide rights to PD-1/VEGF bispecific antibody LM-299, generating total proceeds of $3.288 billion including $888 million upfront payment and technology transfer milestones.

To date, Shanghai Laixin Pharmaceuticals has out-licensed nearly $4 billion worth of assets, equivalent to approximately ¥30 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1118407144"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118407144\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118407144?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118407144","market":"us","top_or_hot":-1,"title":"Sino Biopharmaceutical Surges 5% in Early Trading with $500 Million Acquisition of Shanghai Laixin Pharmaceuticals","media":"Market Watcher","content":"<p>Sino Biopharmaceutical (01177.HK) opened over 5% higher in Hong Kong trading. At press time, shares gained 1.88% to HK$6.49 with turnover reaching HK$706 million.</p>\n<p>The pharmaceutical giant announced a $500 million deal to acquire 95.09% equity in Shanghai Laixin Pharmaceuticals. Combined with its existing 4.91% stake obtained during Laixin's Series C funding, this transaction will make Laixin a wholly-owned subsidiary of Sino Biopharmaceutical.</p>\n<p>Industry records reveal Laixin's significant licensing achievements: In May 2023, AstraZeneca secured exclusive global rights to develop and commercialize LM-305, involving $55 million upfront payment plus potential milestones up to $545 million. By November 2024, Merck & Co. obtained worldwide rights to PD-1/VEGF bispecific antibody LM-299, generating total proceeds of $3.288 billion including $888 million upfront payment and technology transfer milestones.</p>\n<p>To date, Shanghai Laixin Pharmaceuticals has out-licensed nearly $4 billion worth of assets, equivalent to approximately ¥30 billion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical Surges 5% in Early Trading with $500 Million Acquisition of Shanghai Laixin Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical Surges 5% in Early Trading with $500 Million Acquisition of Shanghai Laixin Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n2025-07-16 10:00 北京时间&nbsp;&nbsp;&nbsp;<strong>Market Watcher</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sino Biopharmaceutical (01177.HK) opened over 5% higher in Hong Kong trading. At press time, shares gained 1.88% to HK$6.49 with turnover reaching HK$706 million.\nThe pharmaceutical giant announced a ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1118407144","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118407144","pubTimestamp":1752631238,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"Sino Biopharmaceutical (01177.HK) opened over 5% higher in Hong Kong trading. At press time, shares gained 1.88% to HK$6.49 with turnover reaching HK$706 million. The pharmaceutical giant announced a...","collect":0,"end_time":0,"defaultTopTitle":"laohu8.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1574":"生物医药B类股","BK1515":"抗疫概念","09939":"开拓药业-B","BK1191":"制药","BK1161":"生物科技","01477":"欧康维视生物-B"},"translate_title":"中国生物制药5亿美元收购上海莱欣药业，早盘飙升5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"01477":1},"content_text":"Sino Biopharmaceutical (01177.HK) opened over 5% higher in Hong Kong trading. At press time, shares gained 1.88% to HK$6.49 with turnover reaching HK$706 million.\nThe pharmaceutical giant announced a $500 million deal to acquire 95.09% equity in Shanghai Laixin Pharmaceuticals. Combined with its existing 4.91% stake obtained during Laixin's Series C funding, this transaction will make Laixin a wholly-owned subsidiary of Sino Biopharmaceutical.\nIndustry records reveal Laixin's significant licensing achievements: In May 2023, AstraZeneca secured exclusive global rights to develop and commercialize LM-305, involving $55 million upfront payment plus potential milestones up to $545 million. By November 2024, Merck & Co. obtained worldwide rights to PD-1/VEGF bispecific antibody LM-299, generating total proceeds of $3.288 billion including $888 million upfront payment and technology transfer milestones.\nTo date, Shanghai Laixin Pharmaceuticals has out-licensed nearly $4 billion worth of assets, equivalent to approximately ¥30 billion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}